Skip to content

Pemivibart safe, effective for prevention of COVID-19 in immunocompromised cancer patients
Golcadomide improves first-line treatment for aggressive B-cell lymphoma
FDA grants orphan drug designation to EO2463 to treat indolent non-Hodgkin lymphoma
FDA approves pivekimab sunirine-pvzy for BPDCN
Study shows ‘encouraging’ conditioning regimen for patients with relapsed or refractory acute leukemia

Insider Reader Survey

Join SOHO

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

MPN News

Leukemia Acute Lymphoblastic Leukemia Myeloproliferative Neoplasms News

Pathways & Perspectives with Gabriela Hobbs, MD

by SOHO Insider Editors
October 27, 2025
0 Comments

EHA 2025 Myeloproliferative Neoplasms Video Interviews

Novel therapy INCA in ET shows positive results in early-phase data

by Leah Sherwood
July 18, 2025
0 Comments

EHA 2025 Meetings / Conferences Myeloproliferative Neoplasms

Dr. Kuykendall from EHA 2025: ‘the research is as hot as the conference center’

by SOHO Insider Editors
June 13, 2025
0 Comments

Myeloproliferative Neoplasms SOHO Insider Podcast

Drs. Kuykendall and Hobbs on MPN care in 2025

by Leah Sherwood
June 2, 2025
0 Comments

Rio de Janeiro, Brazil - September 10, 2020: ANVISA, National Health Surveillance Agency, on smartphone screen. In Brazil, it exercises sanitary control over all products and services

Myeloproliferative Neoplasms Polycythemia Vera News

ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera

by SOHO Insider Editors
March 25, 2025
0 Comments

Myeloproliferative Neoplasms

Addition of ropeginterferon alfa-2b to standard PV care is cost effective

by SOHO Insider Editors
February 28, 2025
0 Comments

Leukemia Lymphoma Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Neoplasms News Society Updates

Abstract submissions now open for SOHO 2025

by Leah Sherwood
February 14, 2025
0 Comments

Myeloproliferative Neoplasms Primary Myelofibrosis

Is SVR linked to survival benefit in pacritinib-treated patients with myelofibrosis?

by SOHO Insider Editors
January 28, 2025
0 Comments

Myeloproliferative Neoplasms Primary Myelofibrosis

Do driver mutations influence treatment outcomes in myelofibrosis?

by Leah Sherwood
January 10, 2025
0 Comments

Myeloproliferative Neoplasms Polycythemia Vera

Orphan Drug Designation granted to selective JAK2 inhibitor for treatment of polycythemia vera

by SOHO Insider Editors
January 6, 2025
0 Comments

1
2
3

Top Categories

Cellular Therapy

72

Leukemia

112

Lymphoma

125

Multiple Myeloma

94

Myelodysplastic Syndromes

39

Myeloproliferative Neoplasms

22

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

MPN News

Pathways & Perspectives with Gabriela Hobbs, MD

Novel therapy INCA in ET shows positive results in early-phase data

Dr. Kuykendall from EHA 2025: ‘the research is as hot as the conference center’

Drs. Kuykendall and Hobbs on MPN care in 2025

ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera

Addition of ropeginterferon alfa-2b to standard PV care is cost effective

Abstract submissions now open for SOHO 2025

Is SVR linked to survival benefit in pacritinib-treated patients with myelofibrosis?

Do driver mutations influence treatment outcomes in myelofibrosis?

Orphan Drug Designation granted to selective JAK2 inhibitor for treatment of polycythemia vera

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Recent Posts

Pemivibart safe, effective for prevention of COVID-19 in immunocompromised cancer patients

Golcadomide improves first-line treatment for aggressive B-cell lymphoma

FDA grants orphan drug designation to EO2463 to treat indolent non-Hodgkin lymphoma

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

Follow Us

MPN News

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms